Rohan Bythell-Douglas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rohan Bythell-Douglas has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Deans
St Vincents Institute of Medical Research
3 shared publications Alexander P Sobinoff
Children's Medical Research Institute , Westmead , NSW
1 shared publication- Chandrika N. Deshpande
The University of Sydney
1 shared publication - Haritha Krishna Sudhakar
The University of Sydney
1 shared publication - Hilda A. Pickett
Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales 2145, Australia
1 shared publication Jixuan Gao
Children's Medical Research Institute , Westmead , NSW
1 shared publication
Latest Publications
- Open Access
- 5 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Cell-active peptide inhibitors of the FANCM-RMI interaction
The FANCM-RMI protein-protein interaction plays an essential role in cancers that extend their telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. Here, we report the first cell-active peptide inhibitors of FANCM-RMI. Screening of mRNA-displayed peptide libraries treated with trans-1,4-dibromo-2-butene led to the discovery of both linear and cyclic peptide hits that bind RMI at the FANCM interaction site. The most potent peptides engage RMI with nanomolar affinity (KD = 4-31 nM) and outcompete the native peptide mimic of FANCM (IC50 = 24-155 nM). A bound X-ray crystal structure of the top hit revealed novel interactions at the RMI binding site not found in the native interaction. Conjugation to a cell-penetrating peptide resulted in inhibitors that induced an antiproliferative effect in ALT-positive osteosarcoma cell lines. These inhibitors represent the first bioactive RMI binders that can be used as chemical tools for studying the involvement of FANCM-RMI in ALT-driven cancers.
- 5 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCell-active peptide inhibitors of the FANCM-RMI interaction
The FANCM-RMI protein-protein interaction plays an essential role in cancers that extend their telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. Here, we report the first cell-active peptide inhibitors of FANCM-RMI. Screening of mRNA-displayed peptide libraries treated with trans-1,4-dibromo-2-butene led to the discovery of both linear and cyclic peptide hits that bind RMI at the FANCM interaction site. The most potent peptides engage RMI with nanomolar affinity (KD = 4-31 nM) and outcompete the native peptide mimic of FANCM (IC50 = 24-155 nM). A bound X-ray crystal structure of the top hit revealed novel interactions at the RMI binding site not found in the native interaction. Conjugation to a cell-penetrating peptide resulted in inhibitors that induced an antiproliferative effect in ALT-positive osteosarcoma cell lines. These inhibitors represent the first bioactive RMI binders that can be used as chemical tools for studying the involvement of FANCM-RMI in ALT-driven cancers.
- Open Access
- 27 August 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (18) , 11029-11044
Mechanism of structure-specific DNA binding by the FANCM branchpoint translocase
FANCM is a DNA repair protein that recognizes stalled replication forks, and recruits downstream repair factors. FANCM activity is also essential for the survival of cancer cells that utilize the Alternative Lengthening of Telomeres (ALT) mechanism. FANCM efficiently recognizes stalled replication forks in the genome or at telomeres through its strong affinity for branched DNA structures. In this study, we demonstrate that the N-terminal translocase domain drives this specific branched DNA recognition. The Hel2i subdomain within the translocase is crucial for effective substrate engagement and couples DNA binding to catalytic ATP-dependent branch migration. Removal of Hel2i or mutation of key DNA-binding residues within this domain diminished FANCM’s affinity for junction DNA and abolished branch migration activity. Importantly, these mutant FANCM variants failed to rescue the cell cycle arrest, telomere-associated replication stress, or lethality of ALT-positive cancer cells depleted of endogenous FANCM. Our results reveal the Hel2i domain is key for FANCM to properly engage DNA substrates, and therefore plays an essential role in its tumour-suppressive functions by restraining the hyperactivation of the ALT pathway.
- 27 August 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (18) , 11029-11044
Open AccessMechanism of structure-specific DNA binding by the FANCM branchpoint translocase
FANCM is a DNA repair protein that recognizes stalled replication forks, and recruits downstream repair factors. FANCM activity is also essential for the survival of cancer cells that utilize the Alternative Lengthening of Telomeres (ALT) mechanism. FANCM efficiently recognizes stalled replication forks in the genome or at telomeres through its strong affinity for branched DNA structures. In this study, we demonstrate that the N-terminal translocase domain drives this specific branched DNA recognition. The Hel2i subdomain within the translocase is crucial for effective substrate engagement and couples DNA binding to catalytic ATP-dependent branch migration. Removal of Hel2i or mutation of key DNA-binding residues within this domain diminished FANCM’s affinity for junction DNA and abolished branch migration activity. Importantly, these mutant FANCM variants failed to rescue the cell cycle arrest, telomere-associated replication stress, or lethality of ALT-positive cancer cells depleted of endogenous FANCM. Our results reveal the Hel2i domain is key for FANCM to properly engage DNA substrates, and therefore plays an essential role in its tumour-suppressive functions by restraining the hyperactivation of the ALT pathway.